Cover Image
市場調查報告書

癌症治療的並用抗體療法概要

Combination Antibody Therapy for Cancer Treatment Overview

出版商 Insight Pharma Reports 商品編碼 351309
出版日期 內容資訊 英文 116 Pages
訂單完成後即時交付
價格
Back to Top
癌症治療的並用抗體療法概要 Combination Antibody Therapy for Cancer Treatment Overview
出版日期: 2016年01月31日 內容資訊: 英文 116 Pages
簡介

重組抗體過去20來,是在醫藥品產業發光的寶石。現在,並用抗體療法成為治療骨髓惡性腫瘤和固態腫瘤的最基本策略之一。

本報告提供癌症治療的抗體藥物的臨床性有效性與市場趨勢,並用抗體治療預測,標的抗體療法和免疫抗體療法,化療和免疫抗體療法的組合,融合抗體療法等概要,以及市場的趨勢,專家的見解等彙整資料。

摘要整理

背景

本報告網羅的專題

並用抗體療法預測

第1章 簡介

第2章 標的抗體療法

  • 可利用的癌症基因
  • 表觀基因
  • 與抗體並用的化療
  • 標的抗體的組合
  • 標的抗體療法與市場
  • 臨床中標的抗體療法
  • 摘要

第3章 免疫抗體療法

  • 發展和目前產品
  • 化療和免疫抗體療法的組合
  • 免疫抗體的組合
  • 市場上免疫抗體治療方法
  • 臨床的免疫抗體療法
  • 摘要

第4章 融合抗體療法

  • 抗體藥物結合體
  • 抗體生物學的結構
  • 免疫細胞激素
  • 與其他藥物組合中的融合抗體
  • 摘要

第5章 複合標的及多官能抗體療法

  • 雙特異性及雙重標的抗體臨床研究趨勢
  • 組調換多株抗體
  • 聯合治療
  • 製造的課題
  • 法律規章領域:課題
  • 摘要

第6章 專利期限和生技仿製藥的登場

  • 簡介
  • 該市場的生技仿製藥抗體
  • 專利期限接近的標靶產品
  • 生技改良藥預測
  • 修飾抗體的明亮未來
  • 摘要

第7章 交易與市場

  • 合併、收購
  • 全合併的起源
  • 摘要

第8章 策略性課題

  • 基礎研究和臨床研究的調整
  • 腫瘤學的新方法:診斷和治療
  • 機會及陷阱
  • 摘要

第9章 對該領域專家的採訪

第10章 抗體技術的發展相關產業相關人員詢問調查

  • 參考資訊
  • 關於Cambridge Healthtech Institute

圖表

目錄

Recombinant antibodies have been the shining jewels in the firmament of the pharma industry for almost the last two decades. They have returned billions of dollars in sales, and if their performance has not been the unalloyed triumph that was foreseen at their inception, they have, at least in some instances, produced impressive gains in patient response. Today they are one of the most fundamental strategies for treating patients with hematological malignancies and solid tumors. This report explores the next level of therapy, combining antibodies with additional agents.

The report consists of eight chapters that address different aspects of the issue of combined antibody therapy - past, present, and future, topics include:

  • A brief review of the clinical efficacy and market status of currently approved antibody-based drugs for cancer therapy
  • Outlook for combination antibody therapeutics
  • Targeted Antibody Therapeutics & Immuno-Antibody Therapeutics
  • Development and Current Products
  • Combination of Chemotherapy and Immuno-antibody therapeutics
  • Combinations of immune-antibodies
  • Immuno- antibody therapeutics in the marketplace
  • Fusion Antibody Therapeutics
  • Multitargeted and Polyfunctional Antibody Therapeutics
  • Patent Expiration and the Rise of Biosimilars
  • Biosimilar antibodies in the market
  • Deals and the Marketplace
  • Interviews with Leading Experts:
    • Interview with Esper Boel, SVP, head of discovery; Ivan Horak, CSO; and Mads Laustsen, CMO at Symphogen
    • Interview with Eric S. Langer, Managing Partner, BioPlan Associates, Inc.
    • Interview with Dr. Laurent Ducry, Group Leader Bioconjugates R&D, Lonza, Valais, Switzerland
    • Interview with Dr. Cheng Liu, CEO, Eureka Therapeutics
    • Interview with Steve King, President, Peregrine Pharma
  • Survey with data from Industry Representatives Concerning Developments in Antibody Technology

Table of Contents

Executive Summary

Background

Topics covered in this report

  • Chapter 1
  • Chapter 2
  • Chapter 3
  • Chapter 4
  • Chapter 5
  • Chapter 6
  • Chapter 7
  • Chapter 8

Outlook for combination antibody therapeutics

CHAPTER - 1

  • Introduction, Scope and Objectives
  • A brief review of the clinical efficacy and market status of currently approved antibody-based drugs for cancer therapy
  • Bevacizumab
  • Necitumumab
  • Dinutuximab.
  • Nivolumab.
  • Blinatumomab
  • Pembrolizumab
  • Ramucirumab
  • Obinutuzumab
  • Ado-trastuzumab emtansine
  • Ipilimumab: Immune checkpoint inhibitors
  • Pertuzumab.
  • Opportunities and challenges for future development
  • 1.2.1. A need for targets.
  • Safety concerns.
  • Objectives and outlook for combination antibody therapy
  • 1.3.1. Overcoming resistance to anti-cancer agents.
  • 1.3.2. Uncertainties in combined antibody therapy.
  • 1.4. Summary

CHAPTER - 2

  • Targeted Antibody Therapeutics
  • 2.1. The unstable cancer genome.
  • 2.2. The epigenome.
  • 2.3. Chemotherapy treatment combined with antibodies
  • 2.4. Combinations of targeted antibodies
  • 2.5. Targeted antibody therapeutics and the marketplace
  • 2.6. Targeted antibody therapeutics in the clinic
  • 2.7. Summary

CHAPTER - 3

  • Immuno-Antibody Therapeutics
  • Development and Current Products
  • Combination of Chemotherapy and Immuno-antibody therapeutics
  • Combinations of immune-antibodies
  • Immuno- antibody therapeutics in the marketplace
  • 3.5. Immuno- antibody therapeutics in the clinic
  • Summary

CHAPTER - 4

  • Fusion Antibody Therapeutics
  • 4.1. Antibody Drug Conjugates (ADCs)
  • Antibody Biologic Constructs (ABCs)
  • Immunocytokines
  • Fusion antibodies in combination with other drugs
  • Summary

CHAPTER - 5

  • Multitargeted and Polyfunctional Antibody Therapeutics
  • 5.1. Status and clinical studies of Bispecific and bi-targeted antibodies
  • 5.2. Recombinant polyclonal antibodies
  • 5.3. Combination therapy
  • 5.4. Challenges in manufacturing
  • 5.5. Regulatory areas: Challenges
  • 5.5. Summary

CHAPTER - 6

  • Patent Expiration and the Rise of Biosimilars
  • 6.1. Introduction
  • Biosimilar antibodies in the market
  • Target products nearing patent expiration
  • Prospects for biobetters
  • A bright future for modified antibodies
  • Summary

CHAPTER - 7

  • Deals and the Marketplace
  • 7.1. Mergers and acquisitions
  • 7.3. The Mother of all Mergers
  • 7.4. Summary

CHAPTER - 8

  • Strategic Issues
  • 8.1. Balancing basic and clinical research
    • 8.1.1. A troubled time for the life sciences
    • 8.1.2. Shoddy and questionable research
    • 8.1.3. A resolution to the funding crisis?
    • 8.1.4. Promising areas of discovery in cancer combination therapies
      • 8.1.4.1. CTLA-4.
      • 8.1.4.2. CD-38.
      • 8.1.4.3. Rectal cancer therapies
  • New approaches to oncology: Diagnostics versus therapeutics
  • 8.2.1. The frustrating search for effective disease biomarkers
  • 8.2.2. A mix of approaches to cancer biomarker discovery.
  • 8.2.3. Three approaches to immunodiagnostic cancer markers
    • 8.2.3.1. The first is the traditional approach of characterization of a single cancer-related marker and its validation as an immunodiagnostic test.
    • 8.2.3.2. The second approach has evolved as sophisticated instrumentation for multiplexing has become more widely available.
    • 8.2.3.3. Yet a third approach is a more indirect one - identifying tumor-specific antibodies in the serum of affected individuals.
  • 8.2.4. Current cancer markers in use
  • 8.3. Opportunities and pitfalls
    • 8.3.1. NCI-MATCH trials
    • 8.3.2. A wide range of treatments offers better odds of survival.
  • Summary

CHAPTER - 9

  • Interviews with Experts in the Field
  • 9.1. Interview with Esper Boel, SVP, head of discovery; Ivan Horak, CSO; and Mads Laustsen, CMO at Symphogen
  • 9.2. Interview with Eric S. Langer, Managing Partner, BioPlan Associates, Inc.
  • 9.3. Interview with Dr. Laurent Ducry, Group Leader Bioconjugates R&D, Lonza, Valais, Switzerland
  • 9.4. Interview with Dr. Cheng Liu, CEO, Eureka Therapeutics
  • 9.5. Interview with Steve King, President, Peregrine Pharma

CHAPTER - 10

  • Questionnaire put to Industry Representatives Concerning Developments in Antibody Technology
  • References
  • About Cambridge Healthtech Institute

FIGURES

  • Figure 1.1.7.1 Ramucirumab (CyramzaTM)
  • Figure 1.1.8.1. Timeline for development of ipilimumab
  • Figure 1.1.11.1. Binding sites on human epidermal growth factor receptor 2 (HER2) for FDA-approved HER2-directed therapies
  • Figure 2.1. Mechanisms that drive drug resistance in cancer cells
  • Figure 2.2.1. Depiction of the Primary Mechanisms that Enable Cancer Cells to Become Drug Resistant
  • Figure 3.1.1. Flash Gordon Comic Strip from the 1950s
  • Figure 3.1. The Il-2 pathway
  • Figure 3.2.1. MAPK Pathway and Mechanism of Vemurafenib
  • Figure 3.3.1. Domain Architecture and Affinity Purification of a scFv:CD40L Fusion Proteins
  • Figure 5.1.1. Alternative possibilities for bispecific Antibodies
  • Figure 8.1.1 Autocrine and Paracrine Loops in SCLC
  • Figure 8.2.1.1. Biomarker discovery over the last 30 years
  • Figure 8.4.1. Rate of new drug approvals

TABLES

  • Table 1.1. FDA-Approved Epigenetic Therapies
  • Table 3.1.1. Currently Approved Non-mAb Anticancer Immunotherapeutics
  • Table 4.1.1. Seattle Genetics ADCs in clinical trials
  • Table 5.2.1. Examples of Oligoclonal and polyclonal antibody therapeutics in development
  • Table 6.1.1 Estimated Patent Expiry Dates
  • Table 7.1. Merger and Acquisition Trends
  • Table 8.1. National R&D by Funder
Back to Top